Literature DB >> 26206532

Design characteristic of randomised controlled trials for geographic atrophy in age-related macular degeneration: selection of outcomes and sample size calculation.

A K Krezel1, R E Hogg1, S Krezel2, R Fallis3, A Azuara-Blanco1.   

Abstract

PURPOSE: The selection of suitable outcomes and sample size calculation are critical factors in the design of a randomised controlled trial (RCT). The goal of this study was to identify the range of outcomes and information on sample size calculation in RCTs on geographic atrophy (GA).
METHODS: We carried out a systematic review of age-related macular degeneration (AMD) RCTs. We searched MEDLINE, EMBASE, Scopus, Cochrane Library, www.controlled-trials.com, and www.ClinicalTrials.gov. Two independent reviewers screened records. One reviewer collected data and the second reviewer appraised 10% of collected data. We scanned references lists of selected papers to include other relevant RCTs.
RESULTS: Literature and registry search identified 3816 abstracts of journal articles and 493 records from trial registries. From a total of 177 RCTs on all types of AMD, 23 RCTs on GA were included. Eighty-one clinical outcomes were identified. Visual acuity (VA) was the most frequently used outcome, presented in 18 out of 23 RCTs and followed by the measures of lesion area. For sample size analysis, 8 GA RCTs were included. None of them provided sufficient Information on sample size calculations.
CONCLUSIONS: This systematic review illustrates a lack of standardisation in terms of outcome reporting in GA trials and issues regarding sample size calculation. These limitations significantly hamper attempts to compare outcomes across studies and also perform meta-analyses.

Entities:  

Mesh:

Year:  2015        PMID: 26206532      PMCID: PMC4815658          DOI: 10.1038/eye.2015.132

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  21 in total

1.  How to calculate sample size in randomized controlled trial?

Authors:  Baoliang Zhong
Journal:  J Thorac Dis       Date:  2009-12       Impact factor: 2.895

2.  Driving up the quality and relevance of research through the use of agreed core outcomes.

Authors:  Paula Williamson; Douglas Altman; Jane Blazeby; Michael Clarke; Elizabeth Gargon
Journal:  J Health Serv Res Policy       Date:  2012-01

3.  The estimation of approximate sample size requirements necessary for clinical and epidemiological studies in vision sciences.

Authors:  E A Goodall; J Moore; T Moore
Journal:  Eye (Lond)       Date:  2009-05-15       Impact factor: 3.775

Review 4.  Outcome measures to assess efficacy of treatments for age-related macular degeneration.

Authors:  Janet Wittes; Matthew Downs
Journal:  Ophthalmology       Date:  2009-10       Impact factor: 12.079

Review 5.  Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment.

Authors:  Jason S Slakter; Michael Stur
Journal:  Surv Ophthalmol       Date:  2005 May-Jun       Impact factor: 6.048

Review 6.  Current knowledge and trends in age-related macular degeneration: today's and future treatments.

Authors:  Raul Velez-Montoya; Scott C N Oliver; Jeffrey L Olson; Stuart L Fine; Naresh Mandava; Hugo Quiroz-Mercado
Journal:  Retina       Date:  2013-09       Impact factor: 4.256

7.  Visual acuity as an outcome measure in clinical trials of retinal diseases.

Authors:  Roy W Beck; Maureen G Maguire; Neil M Bressler; Adam R Glassman; Anne S Lindblad; Frederick L Ferris
Journal:  Ophthalmology       Date:  2007-10       Impact factor: 12.079

Review 8.  Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review.

Authors:  Jonathan A Cook; Jennifer Hislop; Temitope E Adewuyi; Kirsten Harrild; Douglas G Altman; Craig R Ramsay; Cynthia Fraser; Brian Buckley; Peter Fayers; Ian Harvey; Andrew H Briggs; John D Norrie; Dean Fergusson; Ian Ford; Luke D Vale
Journal:  Health Technol Assess       Date:  2014-05       Impact factor: 4.014

9.  Developing core outcome sets for clinical trials: issues to consider.

Authors:  Paula R Williamson; Douglas G Altman; Jane M Blazeby; Mike Clarke; Declan Devane; Elizabeth Gargon; Peter Tugwell
Journal:  Trials       Date:  2012-08-06       Impact factor: 2.279

10.  OMERACT: an international initiative to improve outcome measurement in rheumatology.

Authors:  Peter Tugwell; Maarten Boers; Peter Brooks; Lee Simon; Vibeke Strand; Leanne Idzerda
Journal:  Trials       Date:  2007-11-26       Impact factor: 2.279

View more
  1 in total

1.  Decreased Visual Function Scores on a Low Luminance Questionnaire Is Associated with Impaired Dark Adaptation.

Authors:  Mohammad Yazdanie; Jason Alvarez; Elvira Agrón; Wai T Wong; Henry E Wiley; Frederick L Ferris; Emily Y Chew; Catherine Cukras
Journal:  Ophthalmology       Date:  2017-06-08       Impact factor: 12.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.